contentSlug

type

ContentSlug_ContentQuery

slug

ContentPageContentQuery

content

trendingContent

query ContentSlug_ContentQuery(
  $contentSlug: String!
  $type: [ContentType!]
) {
  ...ContentPageContentQuery_13QmVO
}

fragment CompanyDetails_Content on Content {
  __isContent: __typename
  companies {
    name
    description
    pageUrl
    id
  }
}

fragment ContentBasicInfo on Content {
  __isContent: __typename
  id
  type
  title
  lang
  companies {
    viewerIsFollowing
    id
    name
    pageUrl
  }
  tags {
    viewerIsFollowing
    id
    name
    pageUrl
  }
  ...PublishingDetails
  ...Reactions
}

fragment ContentMetadata on Content {
  __isContent: __typename
  type
  title
  lang
  pageUrl
  alternatePageUrls: translations {
    __typename
    pageUrl
    lang
  }
  imgUrl
  description
  ... on Video {
    liveTime
    videoUrl
  }
  ... on Webcast {
    liveTime
    videoUrl
  }
}

fragment ContentPageContentQuery_13QmVO on Query {
  content(slug: $contentSlug, type: $type) {
    __typename
    id
    type
    title
    isPremium
    lang
    htmlBody
    summary
    companies {
      forum {
        latestPosts {
          ...ForumPosts
        }
      }
      name
      id
      viewerIsFollowing
      pageUrl
      defaultInstrument {
        isin
        id
        marketOpen
        marketClose
        marketplace {
          region
        }
        returns {
          total
        }
      }
    }
    tags {
      viewerIsFollowing
      id
      name
      pageUrl
    }
    createdAt
    ... on Video {
      liveTime
    }
    ... on Webcast {
      liveTime
    }
    slug
    ... on CompanyReport {
      reportUrl
    }
    ... on ThirdPartyCompanyReport {
      reportUrl
    }
    ... on StockExchangeRelease {
      reportUrl
    }
    ...ContentBasicInfo
    ...ContentMetadata
    ...PriceAndRecommendation_Content
    ...CompanyDetails_Content
    ...ReportLink_Content
    ...KeyFigures_Content
  }
  ...TrendingContent_1jQ2Cn
}

fragment ForumPosts on ForumPost {
  text
  likesCount
  url
  author
  postedAt
  authorImgUrl
}

fragment KeyFigures_Content on Content {
  __isContent: __typename
  companies {
    defaultInstrument {
      estimateData {
        modelType
        reportingCurrency
      }
      snapshot {
        transaction {
          date
          actualized {
            year
            quarter
            revenue
            revenueGrowth
            ebitAdjusted
            ebitReported
            ebitda
            enterpriseValue
            epsAdjusted
            dividend
            dividendYield
            sharePrice
          }
          estimates {
            year
            quarter
            revenue
            revenueGrowth
            ebitAdjusted
            ebitReported
            ebitda
            enterpriseValue
            epsAdjusted
            dividend
            dividendYield
            sharePrice
          }
        }
      }
      id
    }
    id
  }
}

fragment PriceAndRecommendation_Content on Content {
  __isContent: __typename
  createdAt
  companies {
    name
    pageUrl
    defaultInstrument {
      priceData {
        tradeCurrency
      }
      snapshot {
        priceData {
          date
          lastPrice
          tradeCurrency
        }
        transaction {
          date
          recommendation
          targetPrice
        }
        prevTransaction {
          recommendation
        }
      }
      id
    }
    id
  }
}

fragment PublishingDetails on Content {
  __isContent: __typename
  createdAt
  publishers {
    name
    imgUrl
  }
  authors {
    __typename
    id
    name
    slug
    imgUrl
    jobTitle
  }
  ... on Video {
    liveTime
  }
  ... on Webcast {
    liveTime
  }
}

fragment Reactions on Content {
  __isContent: __typename
  id
  reactionGroups {
    reactionType
    reactionsCount
    viewerReacted
  }
}

fragment ReportLink_Content on Content {
  __isContent: __typename
  type
  isPremium
  ... on CompanyReport {
    reportUrl
  }
  ... on ThirdPartyCompanyReport {
    reportUrl
  }
  ... on StockExchangeRelease {
    reportUrl
  }
}

fragment TrendingContent_1jQ2Cn on Query {
  trendingContent(type: ARTICLE) {
    __typename
    id
    title
    lang
    pageUrl
    createdAt
    type
    imgUrl
    companies {
      squareLogoUrl
      name
      id
    }
    authors {
      __typename
      imgUrl
      id
    }
    publishers {
      imgUrl
    }
  }
}


rene-eve-appointed-as-director-of-operations-of-bioretec-ltd

__typename

title

isPremium

lang

htmlBody

summary

companies

createdAt

publishers

authors

reactionGroups

pageUrl

translations

imgUrl

description

Bioretec operates in the medical technology sector. The company specializes in the development of medical technology products. The product portfolio includes, for example, implants for pediatric and adult orthopedics and other materials for bone and soft tissue injuries. In addition to the main business, service and related ancillary services are also offered. The business is operated globally with the largest presence in the Nordic region.

Thanks for this. It makes you think…we are comfortably in the red, but nothing is (yet) lost.

Investors have certainly had to wait, and are still waiting quite patiently, for this to break through. In my opinion, the product itself, its purpose, and the benefits it brings are quite a no-brainer deal from the consumer’s perspective. However, commercialization and sales haven’t really taken off much after obtaining the permits, even though the product itself seems excellent. The forum has probably discussed the market’s readiness to “receive” the product before, and there has been talk, among other things, about whether business takes precedence with the idea of more surgeries = more money for hospitals, or if the still scarce indications could be a limiting factor for adoption? Or is the reason why the product isn’t selling simply that there are shortcomings in sales expertise in one way or another? By the end of the year, we will hear about the future directions as the company publishes its strategy update and new financial targets. This is likely the next clear catalyst that might sway the stock price in one direction or another. This year’s performance has also been quite brisk, so many will probably find it easy to make tax-loss sales from this, and perhaps that also weighs on the stock price this December. Next year, a financing round is probably expected again, and with it, some dilution of ownership. It will be interesting to see at what valuation they manage to raise funds in the next offering, and if there will be another offering after that, and then… Perhaps the possibility of an acquisition also lives somewhere in the background? The market capitalization at today’s price seems to be less than 22M€, so it would probably be a bite-sized acquisition for some major player in the field (who?), if they see the product and the R&D pipeline with its permits, etc., as an attractive part of their current operations. The finished product, with its long permit processes, was still more than double the price in the summer. If a takeover bid were made for this, a small premium wouldn’t be enough to get out of this unscathed. All in all, first the slowness of the permit processes and then the launch of sales have certainly managed to surprise me, at least. I made my first purchases from Springvest’s last financing round, topped up a few times after the listing, and used the summer’s warrants. The position is, of course, quite firmly in the red. At the moment, I don’t feel like adding more; instead, I’d gladly wait for some good news with my current position. This probably avoids buying “at the bottom,” but keeps the risks in check.

I have been considering adding to my investment while the valuation is at rock bottom. But… this is quite a rollercoaster when looking at the numbers. What has gone wrong? Is the product not being marketed understandably? Or is it being marketed to the wrong audiences? Are the efforts on the wrong track? By all accounts, the product is ready and functional, patented and protected? My investment horizon is already set for 5 years, but what can really be expected? Money is certainly needed. A potential dilution itself won’t be a disaster, but this is a very ambivalent whole, and that’s why I would appreciate opinions.

Here are Mr. Siltanen’s comments on how Bioretec’s change negotiations have been concluded.  Bioretec announced on Thursday that it had concluded the change negotiations initiated in November. As a result of the negotiations, the company will lay off two employees and furlough five production employees. The targeted savings are moderate in size, and they do not change the company’s big picture. The announcement does not cause immediate changes to our forecasts.                   Inderes              Bioretecin muutosneuvottelut päätökseen - Inderes    Bioretec tiedotti torstaina saaneensa päätökseen marraskuussa aloitetut muutosneuvottelut.

Certainly, if relevant information has been provided, we must now patiently await new steps!

It would be nice to hear an update from the company so that we don’t completely lose hope. One could assume that the restructuring also includes a very intensive search for channels through which sales could pick up. The stock price is at least quite low, but I already bought some more when it felt good. I didn’t buy quite this low, though. It’s affordable to get involved now if you don’t own any yet or to add to your holdings. I personally find it more likely that the wait will eventually pay off than that such a complete and good product would ultimately flop.

If Alan Donze slipped into hiding, it could also be because he simply realized he had messed everything up, burned out… such cases have been seen… It’s just a shame that it fell on Bioretec’s shoulders.

Bioretec

Bioretec Ltd Press release 11. July 2025 at 8.00 amBioretec has appointed Bachelor of Technology René Eve as the company's Director of Operations and as a member of the Management Team. Eve ...

<div class="abstract">Bioretec Ltd&nbsp;&nbsp;&nbsp;Press release&nbsp;&nbsp;&nbsp;11. July 2025 at 8.00 am</div>Bioretec has appointed Bachelor of Technology René Eve as the company's Director of Operations and as a member of the Management Team. Eve has over 15 years of diverse experience in production, procurement, production planning, and customer service. René Eve joins Bioretec from Next Pharma and takes up his duties on 18 August 2025. Esa Hallinen, former Director of Operations, will pursue a career outside Bioretec. &nbsp;"Bioretec is significantly expanding its operations and production after obtaining both U.S. FDA approval and CE Mark approval for the RemeOs™ product family of absorbable orthopedic implants in Europe and all other countries where CE Mark is recognized. René Eve has strong expertise in the pharmaceutical industry and mass manufacturing of metal products.&nbsp;He will play a key role in Bioretec's growth into the next phase of commercialisation for our RemeOs and Activa™ products globally. We are excited to welcome René Eve to our experienced management team," Bioretec's interim CEO Sarah van Hellenberg Hubar-Fisher says.&nbsp;"It's great to join Bioretec's innovative team and support the company's growth and international success story. I am looking forward to implementing the company's strategy and bringing the production of absorbable implants to the next level," René Eve says. <div></div>